BOGOTÁ, Colombia (AP) — Colombian Sen. Miguel Uribe Turbay, who was shot in June during a campaign rally in Bogotá and remains hospitalized, experienced a hemorrhage in his nervous system and is once again in critical condition, authorities said Saturday.
The Fundación Santa Fe clinic that is treating him said in a statement that Uribe Turbay required “urgent neurosurgical procedures” to stabilize him, adding that he was placed under deep sedation to aid his recovery.
Uribe Turbay was shot three times, twice in the head, while giving a campaign speech in a park on June 7. Since then, he has remained in an intensive care unit in serious condition with episodes of slight improvement.
Two months after the attack, his wife, María Claudia Tarazona, posted the following message on Instagram: “My sweet love, I miss you so much that it tears my soul apart. Come back to me, God willing.”
Six people have been prosecuted for the attack, while a minor collaborating in the investigation escaped from a detention center.
Among those arrested is Cristian Camilo González Ardilla, alias “El Costeño,” whom authorities believe was the planner and organizer of the attack and considered key to help investigators track down its masterminds.
FILE - A leaflet showing Colombian Sen. Miguel Uribe Turbay sits on a Colombian national flag draped over his seat in the congressional chamber in Bogota, Colombia, June 9, 2025. (AP Photo/Ivan Valencia, File)
NEWARK, Del.--(BUSINESS WIRE)--Jan 15, 2026--
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/
The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements.
“Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Derek Grimes, Executive Vice President of QPS. “Oracle Argus provides us with a robust, scalable solution to support the growing needs of our customer’s clinical trial portfolios and the evolving expectations of regulatory authorities worldwide.”
“Oracle Argus provides QPS Holdings, LLC with a trusted, globally recognized drug safety platform that supports compliance with stringent pharmacovigilance standards and regulations, while streamlining end-to-end safety operations and insights at scale,” said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. “With our industry-leading solutions, QPS Holdings, LLC can further transform and elevate its safety case management for customers worldwide.”
The deployment of Oracle Argus will enable QPS to:
As the demand for innovative therapies continues to rise, CROs play a critical role in managing both development speed and patient safety. By leveraging the Oracle Argus platform, QPS is well-positioned to deliver on its mission to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services.
###
ABOUT QPS HOLDINGS, LLC
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and India. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, PBMC processing, central safety labs, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I/II clinical units, and multi-site clinical research services. For more information, visit http://www.qps.com or email info@qps.com.
ABOUT ORACLE ARGUS
Oracle Argus is an industry-leading, trusted solution for processing, analyzing, and reporting adverse event cases originating in pre-market and post-market drugs, biologics, vaccines, devices, and combination products. Oracle has been a Leader in the IDC MarketScape: Worldwide Life Science R&D Pharmacovigilance Technology Solutions and Consulting Services 2025 Vendor Assessment (doc # US53669225, July 2025). To learn more about Oracle’s pharmacovigilance portfolio visit: https://www.oracle.com/life-sciences/safety-solutions/argus-safety-case-management/. Trademarks: Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation.
Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC.
